Pulmonary Hypertension: Classification and Pathogenesis
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Hypertension II: Pathophysiology
Pulmonary Embolism I: Introduction
Heart Failure II: Pathophysiology
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Nov 21, 2025

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
Kondababu Kurakula1, Valérie F E D Smolders2, Olga Tura-Ceide3,4,5
1Department of Cell and Chemical Biology, Laboratory for CardioVascular Cell Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Endothelial cell (EC) dysfunction initiates pulmonary arterial hypertension (PAH) by causing abnormal remodeling of pulmonary arteries. Targeting EC dysfunction offers potential therapeutic strategies for PAH.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: